Sunita Dwivedy (Dwivedy) Nasta MD FACP

Hematologic Oncology

Professor of Clinical Medicine

3400 Civic Center BlvdFl 12South PCAMPhiladelphia, PA 19104
Phone+1 215-662-3933
Fax+1 215-615-5887

Dr. Nasta is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Nasta's full profile Already have an account?

Summary

Dr. Sunita (Dwivedy) Nasta is an oncology specialist located in Philadelphia, PA, with a subspecialty in hematologic oncology. She completed her residency in Internal Medicine at Baylor College of Medicine and her fellowship in Hematology and Medical Oncology at the University of Texas Health Science Center at Houston/M D Anderson Cancer Center. She has been a professor at the University of Penn Medical Group and an associate professor at the Hospital of the University of Pennsylvania since 2001. Dr. Nasta's expertise includes conditions such as Langerhans cell histiocytosis, non-Hodgkin lymphoma, and cutaneous T-cell lymphoma of the penis. She has published extensively, including studies in prestigious journals like Blood and The New England Journal of Medicine. Her honors include CMS Meaningful Use Stage Certification and the designation of Regional Top Doctor by Castle Connolly. She is also involved in clinical trials, acting as a principal investigator and contact for studies on Tirabrutinib and CAR-T cell therapy for lymphoma.

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1998 - 2001
Baylor College of MedicineResidency, Internal Medicine, 1995 - 1998
Virginia Commonwealth University School of MedicineClass of 1995
Stanford UniversityBS, Micrbiology/Immunology, Research honors, 1987 - 1991

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

PA State Medical License 2001 - 2026
TX State Medical License 1997 - 2003
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014-2017
CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2012, 2014-2017

Clinical Trials

Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) Start of enrollment: 2021 Dec 29
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator, Contact
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) Start of enrollment: 2021 May 26
RECRUITING
PHASE1
Roles: Contact

Publications & Presentations

PubMed

Decade-long persistence of CD19 CAR T cells in B cell lymphomas.
Luca Paruzzo, Emeline R Chong, Elise A Chong, Zhixuan Zheng, Puneeth Guruprasad
Nature Medicine. 2026-08-10
Clinical features and outcomes of patients with non-erythrodermic mycosis fungoides with high blood tumor burden.
Colin J Thomas, Caroline S Myers, Jina Chung, Daniel Landsburg, Sunita D Nasta
Blood Neoplasia. 2026-08-01
Safe Integration of Radiation Therapy With Bispecific Antibodies in Relapsed/Refractory B-cell Lymphomas.
Jonathan A Baron, Monica Chelius, Gurbani Singh, Michael D Schad, Melanie Berger
Clinical Lymphoma, Myeloma & Leukemia. 2026-07-13

Journal Articles

Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-Exposure SARS-CoV-2 Prophylaxis Among Health Care Workers
Matthew C Hyman, Ian Frank, Scott E Hensley, Saar Gill, Dan T Vogl, Ivan Maillard, Daria V Babushok, Alexander C Huang, Sunita D Nasta, Jennifer C Walsh, Michael C Mil..., JAMA Internal Medicine
International, Evidence-Based Consensus Treatment Guidelines for Idiopathic Multicentric Castleman Disease
Aaron Goodman, Corey Casper, Sudipto Mukherjee, Peter Voorhees, Angela Dispenzieri, David C Fajgenbaum, Razelle Kurzrock, Raj Jayanthan, Sunita Nasta, Thomas S Uldrick..., Blood
Non-Viral RNA Chimeric Antigen Receptor Modified T Cells in Patients with Hodgkin Lymphoma
Stephan A Grupp, Sunita Dwivedy Nasta, Susan R Rheingold, Daniel J Landsburg, Carl H June, Jakub Svoboda, Stephen J Schuster, Saar I Gill, David L Porter, Blood

Abstracts/Posters

Concurrent Use of Novel Agents and Radiation Is Tolerated in Lymphoma Patients
Sunita Dwivedy Nasta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors
Sunita D Nasta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcomes for Double Hit Lymphoma Patients Identified Via Routine Vs Selective Testing for MYC Rearrangement
Sunita Dwivedy Nasta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Hospitalization Patterns with Commercial CAR T-Cell Therapy: A Single Institution Experience
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

OncLive® Presents State of the Science Summit™ on the Treatment of Hematologic MalignanciesSeptember 10th, 2019
Treatment Doctor Tested on Himself Can Put Others into RemissionAugust 13th, 2019
Expert Emphasizes Appropriate Diagnosis, Staging of T-cell LymphomasNovember 30th, 2017